Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

Summary

Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .

Timeline

Start

2021-08-17

Primary completion

2025-07-25

Completion

2025-09-28

Publications

• Results Zeng Z, Huang W, Zeng F, Xiong L, Liu C, Chen Z, Zheng Y, Cai J, Huang L, Zhang X, Liu A. The Efficacy and Safety of Tislelizumab plus Anlotinib as First-line Treatment in Advanced Pulmonary Sarcomatoid Carcinoma: A Single-Arm Phase II Trial. Clin Cancer Res. 2026 Jun 15;32(12):2372-2380. doi: 10.1158/1078-0432.CCR-25-4770.

Drugs

Indications